- Home
- NFBK vs CRMD Comparison
NFBK vs CRMD Comparison
Compare NFBK & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- CRMD
- Stock Information
- Founded
- NFBK 1887
- CRMD 2006
- Country
- NFBK United States
- CRMD United States
- Employees
- NFBK N/A
- CRMD N/A
- Industry
- NFBK Major Banks
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- CRMD Health Care
- Exchange
- NFBK Nasdaq
- CRMD Nasdaq
- Market Cap
- NFBK 406.5M
- CRMD 464.7M
- IPO Year
- NFBK 2007
- CRMD 2010
- Fundamental
- Price
- NFBK $11.50
- CRMD $12.62
- Analyst Decision
- NFBK Buy
- CRMD Strong Buy
- Analyst Count
- NFBK 2
- CRMD 6
- Target Price
- NFBK $13.00
- CRMD $15.00
- AVG Volume (30 Days)
- NFBK 169.9K
- CRMD 2.1M
- Earning Date
- NFBK 07-23-2025
- CRMD 05-06-2025
- Dividend Yield
- NFBK 4.45%
- CRMD N/A
- EPS Growth
- NFBK 1.58
- CRMD N/A
- EPS
- NFBK 0.76
- CRMD 0.28
- Revenue
- NFBK $128,407,000.00
- CRMD $82,553,827.00
- Revenue This Year
- NFBK $10.59
- CRMD $239.16
- Revenue Next Year
- NFBK $15.58
- CRMD $53.17
- P/E Ratio
- NFBK $15.35
- CRMD $45.64
- Revenue Growth
- NFBK N/A
- CRMD N/A
- 52 Week Low
- NFBK $6.98
- CRMD $3.61
- 52 Week High
- NFBK $14.39
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- NFBK 51.06
- CRMD 65.00
- Support Level
- NFBK $11.41
- CRMD $11.88
- Resistance Level
- NFBK $11.99
- CRMD $12.99
- Average True Range (ATR)
- NFBK 0.31
- CRMD 0.46
- MACD
- NFBK -0.05
- CRMD -0.11
- Stochastic Oscillator
- NFBK 25.65
- CRMD 58.44
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.